Mucormycosis: Causes, Risk Factors, and Treatments

Mucormycosis is a severe, often life-threatening fungal infection caused by molds in the order Mucorales, a group of fungi found widely in soil, decaying organic matter, and indoor air. It primarily strikes people whose immune defenses are compromised, and it has a distinctive and alarming ability to invade blood vessels, cutting off blood supply to tissues and causing rapid destruction. The infection drew global attention during the COVID-19 pandemic, when thousands of cases emerged in India alone, but it has long been recognized as one of the most aggressive infections in medicine.

What Causes It

The fungi behind mucormycosis belong to several genera, but three dominate. Rhizopus, Mucor, and Lichtheimia species account for roughly 70 to 80 percent of all cases.¹ Among these, Rhizopus arrhizus (also called Rhizopus oryzae) is the single most common culprit.² Less common species like Cunninghamella bertholletiae sometimes appear, particularly in children with blood cancers.

These molds thrive on decaying organic material. They grow on bread, rotting fruit, compost, animal droppings, and soil between growing seasons. They are heat-tolerant, which helps them survive at human body temperature, and they reproduce by releasing spores (called sporangiospores) that range from about 3 to 11 micrometers across. These spores become airborne easily and float through both outdoor and indoor environments.³ Most people inhale small numbers of Mucorales spores regularly without getting sick. The infection takes hold only when something has gone wrong with the body’s defenses.

How People Get Infected

Inhaling airborne spores is the main route of infection, and it accounts for the two most common forms of the disease: rhino-orbital-cerebral mucormycosis (which starts in the sinuses) and pulmonary mucormycosis (which starts in the lungs).⁴ Construction and excavation projects have been linked to outbreaks of sinus and lung infections, probably because disturbed soil kicks up heavy loads of spores. Contaminated air-conditioning filters have also been implicated.⁵

The skin is the second major entry point. Traumatic implantation of spores through wounds, burns, or even insect bites can cause cutaneous mucormycosis. Natural disasters have produced clusters of skin infections: contaminated dirt and water driven into open wounds by tornadoes and tsunamis have led to outbreaks among survivors.⁶ In hospitals, sporadic infections have been traced to contaminated bandages, adhesive dressings, and even wooden tongue depressors used to splint intravenous lines in premature infants.⁷

One hospital investigation found that Rhizopus species were recovered from over 40 percent of environmental samples taken from clean linens and associated areas, and the same species causing patient infections was isolated from linen delivery bins at an off-site laundry facility.⁸ That finding underscores how pervasive these organisms are and how unexpected the source of an outbreak can be.

Why Certain People Are Vulnerable

A healthy immune system is remarkably effective at neutralizing Mucorales. Neutrophils and macrophages serve as the main line of defense, damaging and degrading fungal spores once they begin to swell and germinate.⁹ Adaptive immune responses, particularly from certain T-cell subsets, further assist in clearing the fungus.¹⁰ When any of these defenses are impaired, mucormycosis gets its opening.

Diabetes mellitus is the single most common underlying condition, present in about 40 percent of cases in a large systematic review of published reports.¹¹ Diabetic ketoacidosis is especially dangerous because the drop in blood pH disrupts the ability of transferrin, the body’s main iron-transport protein, to hold on to iron. In laboratory experiments, acidotic conditions progressively destroyed transferrin’s iron-binding capacity, and when iron was freely available in acidotic serum, Rhizopus grew profusely. At a normal blood pH, no growth occurred.¹²

Other major risk groups include people with blood cancers, organ transplant recipients, and those on high-dose corticosteroids or other immune-suppressing drugs. In organ transplant recipients, renal failure, diabetes, and prior use of certain antifungals (voriconazole and caspofungin) have been identified as independent risk factors.¹³ High-dose corticosteroids, T-cell-depleting therapies, and episodes of graft rejection further raise the risk in this population.¹⁴

The Iron Connection

Iron is central to mucormycosis in a way that sets it apart from most other fungal infections. Mucorales fungi have an unusually high dependence on iron for growth, and essentially every known risk factor for the disease shares one feature: increased availability of free iron in the body.¹⁵

This relationship produced one of the more surprising findings in infectious disease. Deferoxamine, an iron-chelating drug used to treat iron overload in patients with kidney failure, was expected to protect against mucormycosis by removing excess iron. Instead, it does the opposite. Deferoxamine acts as a siderophore for Mucorales, essentially collecting iron and delivering it directly to the fungus. The iron stripped from deferoxamine is transported into the fungal cell through a high-affinity iron permease.¹⁶ Patients receiving deferoxamine therapy have a sharply elevated risk of developing mucormycosis, and this paradox led clinicians to switch to alternative iron chelators that do not supply iron to the fungus.

How the Infection Invades Tissue

The hallmark of mucormycosis is angioinvasion, the direct invasion of blood vessel walls by fungal hyphae. Once inside blood vessels, the fungus triggers clot formation and blocks blood flow, causing tissue to die from lack of oxygen. This is what produces the characteristic rapid, blackened tissue necrosis that clinicians associate with the disease.¹⁷

At the molecular level, researchers have identified how Rhizopus gets inside human cells. The fungus expresses spore coat proteins called CotH on its surface. These proteins bind to a receptor on human endothelial cells called GRP78, allowing the fungus to invade the cells lining blood vessels.¹⁸ When researchers gave non-pathogenic yeast the ability to produce CotH proteins, the yeast gained the ability to invade host cells through the same GRP78 pathway.¹⁹ This finding has made CotH proteins a target for potential future therapies, including antibody-based treatments that block the fungal protein from docking onto human cells.

Angioinvasion also explains why the infection spreads so quickly. In a reported case, a patient with sinus pain progressed to bilateral blood clots in the cavernous sinuses and occlusion of the internal carotid artery within days, and died despite intravenous antifungal therapy. The infection spread through three routes simultaneously: direct tissue extension, along nerve sheaths, and along blood vessel walls.²⁰

Forms of the Disease

Mucormycosis takes several forms depending on where the spores land or enter, and the specific form is closely tied to what underlying condition the patient has.

Rhino-orbital-cerebral mucormycosis is the most widely recognized form and is strongly linked to diabetes. In the systematic review mentioned earlier, diabetes was an independent predictor of this form specifically.²¹ It begins in the sinuses and can spread to the orbit (eye socket) and brain. In one case series, periorbital swelling, eye pain, drooping eyelids, and vision loss appeared in about 87 percent of patients, while facial pain and swelling were present in 80 percent. Roughly 60 percent had nasal discharge or crusting, and over half reported headaches starting days before hospitalization.²²

Pulmonary mucormycosis is more common in people with blood cancers and transplant recipients. A CT scan showing a “reverse halo sign,” a ring of denser tissue surrounding a zone of lower density, can be an early indicator.²³ Organ transplant recipients also face elevated risks of gastrointestinal and disseminated disease, in which the infection spreads to multiple organs.²⁴

Cutaneous mucormycosis typically follows trauma, burns, or surgical wounds. It can occur in people with no underlying immune problems, which distinguishes it from most other forms. An 11-year-old burn patient, for example, developed angioinvasive mucormycosis that led to thrombosis of major blood vessels in the leg and rapidly progressive tissue death.²⁵

Diagnosis

Speed is everything in diagnosing mucormycosis, because the infection can destroy tissue faster than most clinicians expect. Tissue biopsy remains the cornerstone. Under the microscope, Mucorales hyphae have a characteristic look: wide, ribbon-like strands with few internal dividing walls (pauciseptate) and branches that come off at roughly right angles.²⁶ Culture of the biopsy material can identify the specific species, and molecular methods like PCR offer additional sensitivity. In practice, clinicians often start treatment based on the histopathology alone because waiting for culture results can cost critical time.

Imaging plays an important supporting role. CT and MRI help map how far the infection has spread, particularly in the sinuses, orbits, and brain. Early endoscopic examination of the nasal passages in a suspected case is valuable because it can reveal necrotic tissue before the infection extends further.²⁷

Treatment

Mucormycosis demands a two-pronged approach: aggressive antifungal drugs and surgical removal of infected tissue. Neither alone is reliably sufficient.

Liposomal amphotericin B has been the drug of choice for about two decades. It kills fungal cells by binding to ergosterol in their membranes, punching holes that cause the cell to leak and die. European guidelines recommend doses of 5 to 10 mg per kilogram of body weight, with the higher end reserved for infections involving the brain. Doses above 10 mg/kg per day do not reliably produce higher blood levels and increase kidney toxicity.²⁸

Once the acute phase is controlled, patients typically switch to an oral antifungal for long-term treatment. Posaconazole and isavuconazole are the two azole drugs with meaningful activity against Mucorales. A French study of pulmonary mucormycosis found that switching from intravenous amphotericin B to an oral azole after about 14 days appeared to be as effective as longer courses of amphotericin B, with the benefit of reducing side effects.²⁹ A systematic review of isavuconazole use found that combining amphotericin B with an azole during the acute phase yielded the lowest mortality rates, with amphotericin B plus an azole given simultaneously carrying a mortality of under 7 percent, compared with about 32 percent for amphotericin B alone.³⁰

Surgery is not optional in most cases. Repeated debridement of dead and infected tissue removes the fungal burden that drugs alone struggle to penetrate, partly because angioinvasion cuts off the blood supply that would deliver antifungals to the site.³¹ In a large multicenter cohort, patients who received surgical treatment had substantially lower mortality, with a hazard ratio of 0.1 compared to those who did not receive surgery.³² For rhino-orbital-cerebral cases, this sometimes means orbital exenteration, the removal of the eye and surrounding tissue. In a three-year follow-up study, all patients who underwent exenteration survived, whereas the overall mortality for rhino-orbital-cerebral mucormycosis in that cohort reached about 44 percent.³³

Prognosis

Outcomes depend heavily on where the infection is, how quickly it is caught, and what treatment the patient receives. In a multicenter study of 686 patients, about 15 percent died within one year, and nearly two-thirds of deaths happened during the initial hospitalization.³⁴ Independent predictors of death in that cohort included orbital involvement, intracranial spread, ICU admission, and poor blood sugar control. Combination antifungal therapy and surgery were both independently associated with better survival. Survivors in that study showed improved quality of life over time, particularly those who returned to employment.

Disseminated mucormycosis, where the infection has spread to multiple organ systems, carries the worst prognosis. Blood cancers are the strongest predictor of disseminated disease.³⁵

The COVID-19 Surge

During the second wave of COVID-19 in India in 2021, mucormycosis cases spiked so dramatically that the disease earned the colloquial name “black fungus” in news reports. The surge was driven by a convergence of risk factors. Diabetes was present in about 97 percent of COVID-associated mucormycosis patients in one study, and uncontrolled diabetes and newly diagnosed diabetes were both strong independent risk factors. But the most striking association was with steroid use: after adjusting for other variables, corticosteroid treatment carried an odds ratio of about 28 for developing mucormycosis.³⁶

Steroids were widely used during the pandemic to treat severe COVID-19 lung inflammation, and they are genuinely life-saving for critically ill patients. But overuse in mild cases, and in patients with underlying diabetes whose blood sugar spiraled out of control on steroids, created ideal conditions for the fungus. Elevated serum ferritin, a marker of disturbed iron metabolism, was also significantly higher in patients who developed mucormycosis, tying back to the central role of iron availability. Researchers have also proposed that COVID-19 itself may upregulate the GRP78 receptor on endothelial cells, the same receptor the fungus exploits for invasion, potentially making the host more susceptible even before steroids enter the picture.³⁷

Environmental factors may have also played a role. A study of homes of COVID-associated mucormycosis patients in India found that Mucorales spore counts in patients’ bedrooms were significantly higher than in other rooms of the same residence, with air coolers identified as a likely concentrating source.³⁸

Mucormycosis in Children

Pediatric mucormycosis looks different from the adult disease in several ways. In a large registry-based study, the most common underlying condition in children was blood cancer, accounting for about 46 percent of cases, while diabetes, the leading adult risk factor, was present in under 5 percent. Roughly 10 percent of pediatric patients had no identifiable immune problem at all.³⁹

The sites of infection also differ. In children, the lungs and skin each accounted for about 19 percent of cases, the sinuses and orbital region for about 16 percent, and disseminated disease was present in about 38 percent, a higher proportion than typically seen in adults. Despite these differences, the treatment approach is the same: amphotericin B with or without additional antifungals and surgery. The combination of antifungal therapy with surgery was associated with better survival.⁴⁰ One single-center study found that in-hospital mortality was zero among children, compared with about 15 percent in adults, though the children in that cohort also had a notable proportion who were immunocompetent, which likely contributed to their better outcomes.⁴¹

Adjunctive Therapies and Emerging Approaches

Beyond standard antifungals and surgery, researchers have explored several adjunctive treatments. Hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized chamber, has generated interest based on the reasoning that high oxygen concentrations can inhibit fungal growth and improve wound healing in ischemic tissue. Case reports from COVID-associated mucormycosis patients who were failing standard treatment showed improvement after the addition of hyperbaric oxygen therapy alongside continued antifungal treatment and surgery.⁴² Another group found that combining posaconazole, hyperbaric oxygen, and local application of methylene blue after surgical debridement prevented further disease progression in patients with jaw and sinus involvement.⁴³ The evidence remains limited to case reports and small series, so hyperbaric oxygen is not considered standard care, but it represents one of the more promising supportive options for patients who are not responding to conventional treatment.

On the pharmaceutical research front, the discovery of the CotH-GRP78 invasion pathway has opened up the possibility of antibody-based therapies. In mouse models, antibodies targeting CotH3 protected against mucormycosis by blocking the fungus from invading endothelial cells and enhancing the immune system’s ability to engulf and kill spores.⁴⁴ These therapies have not yet reached human trials, but they represent a fundamentally different approach: rather than poisoning the fungus directly, they would block its ability to get inside human tissue in the first place.

Natural Disasters and Wound Infections

Mucormycosis after natural disasters is an underappreciated problem. When high-velocity debris drives contaminated soil and water deep into wounds, the resulting infections can develop days to weeks later and progress rapidly. After the 2011 tornado in Joplin, Missouri, a cluster of cutaneous mucormycosis cases emerged among survivors with penetrating injuries, some of whom developed necrotizing soft-tissue infections that caused substantial morbidity and death.⁴⁵ Similar wound-based infections were documented after the 2004 Asian tsunami.⁴⁶

Fungal wound infections are easily overlooked in disaster settings because the initial focus is on bacteria, and standard wound cultures may not detect Mucorales. Public health experts have called for increased awareness among both clinicians and first responders that disaster-associated wounds contaminated with organic matter should raise suspicion for fungal infection, especially when wounds fail to respond to antibacterial treatment.⁴⁷ Early tissue biopsy of suspicious wounds is the fastest way to catch the infection before it becomes life-threatening.